Neurobiological Markers of Treatment Response for Anxiety and OCD
Recruiting · NCT05663489 · Observational (researchers observe without assigning treatment) · Lead sponsor: Haukeland University Hospital
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Obsessive-compulsive disorder (OCD) and anxiety disorders are common and debilitating conditions which are often chronic when treatment is not provided. International guidelines recommend cognitive behavioral therapy (CBT) as the first-line treatment, and research has shown that CBT can be delivered over a concentrated period of time. The Bergen 4-Day Treatment (B4DT) is an exposure-based treatment which is delivered over four consecutive days. B4DT has been shown to induce rapid and long-lasting remission in around 70% of patients. This provides a platform for studying psychological and neurobiological changes associated with treatment response and non-response. The present study will investigate longitudinal changes in psychological measures and DNA methylation in patients who receive the B4DT, as well as a subset will also undergo multimodal brain imaging.
Who can take part
Inclusion criteria
- Diagnosed with obsessive-compulsive disorder, panic disorder or social anxiety disorder using DSM-5 criteria
- Referred to National Clinic for 4-Day Treatment, Haukeland University Hospital, Bergen, Norway
- Consented to participate in the "Kvalitetsregister for konsentrerte behandlingsformat"
Exclusion criteria
- Suicidal, ongoing mania, primary eating disorder, intellectual disability, ongoing psychosis, ongoing substance abuse
- For MRI substudy:
- Inclusion Criteria:
- \- For the healthy controls, no previous or current psychiatric disorders as detected by the Mini International Neuropsychiatric Interview (MINI)
- Exclusion Criteria:
- \- MRI incompatibility (e.g. pregnancy, metal implants)
Where it is running
1 location listed.
- Bergen Center for Brain Plasticity - Bergen, Vestland, Norway